CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Locally Recurrent Colorectal Cancer

NCT06881537 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Locally Recurrent Colorectal Cancer

Interventions

DRUG: Capecitabine
DRUG: Oxaliplatin
DRUG: Bevacizumab
DRUG: Tislelizumab

Sponsor

Shanghai Changzheng Hospital